TG Therapeutics, Inc. (LON:0VGI)

Market Cap	5.19B
Revenue (ttm)	262.80M
Net Income (ttm)	18.68M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	277.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,023
Average Volume	3,606
Open	37.50
Previous Close	38.55
Day's Range	37.50 - 37.50
52-Week Range	6.47 - 35.58
Beta	n/a
RSI	66.40
Earnings Date	May 5, 2025

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 338
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VGI

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD